INFINITY PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2014 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Infinity Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2014 to Q2 2023.
  • Infinity Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $856K, a 5.03% increase year-over-year.
  • Infinity Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $4.57M, a 43.9% increase year-over-year.
  • Infinity Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.62M, a 34.4% increase from 2021.
  • Infinity Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.7M, a 85.1% increase from 2020.
  • Infinity Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $1.46M, a 31.7% decline from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $4.57M $856K +$41K +5.03% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $4.53M $1.77M +$907K +105% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $3.62M $1.02M +$300K +41.6% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-28
Q3 2022 $3.32M $917K +$146K +18.9% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $3.18M $815K +$143K +21.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $3.03M $867K +$337K +63.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $2.7M $722K +$330K +84.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 $2.37M $771K +$427K +124% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $1.94M $672K +$312K +86.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $1.63M $530K +$170K +47.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $1.46M $392K -$68K -14.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-29
Q3 2020 $1.52M $344K -$83K -19.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $1.61M $360K -$203K -36.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-27
Q1 2020 $1.81M $360K -$323K -47.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $2.13M $460K -$404K -46.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 $2.54M $427K -$429K -50.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $2.97M $563K -$282K -33.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-30
Q1 2019 $3.25M $683K -$200K -22.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $3.45M $864K -$717K -45.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-03
Q3 2018 $4.17M $856K -$731K -46.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-30
Q2 2018 $4.9M $845K -$1.15M -57.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-30
Q1 2018 $6.05M $883K -$924K -51.1% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $6.97M $1.58M -$1.82M -53.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $8.79M $1.59M -$1.2M -43.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 $9.99M $2M -$1.82M -47.6% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $11.8M $1.81M -$1.91M -51.4% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $13.7M $3.4M -$121K -3.44% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 $13.8M $2.79M -$1.03M -26.9% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $14.9M $3.81M +$197K +5.45% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $14.7M $3.72M -$36K -0.96% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $14.7M $3.52M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-15
Q3 2015 $3.82M +$883K +30.1% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 $3.62M +$669K +22.7% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $3.75M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-04
Q3 2014 $2.93M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-05
Q2 2014 $2.95M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.